INTRODUCTION
High-starch diets contribute to subacute ruminal acidosis (SARA) and also typically increase starch fermentation in the large intestine (Van Soest, 1994; Gressley et al., 2011; Li et al., 2012) . As a consequence, diarrhea, frothy feces, and presence of mucin casts are used as field indicators of SARA (Hall, 2002; Plaizier et al., 2008) . Systemic inflammatory responses to SARA are proposed that result from breaches in digestive epithelial barrier function that allow for passage of toxic compounds into the submucosa (Steele et al., 2011; Li et al., 2012) , but whether and where these breaches occur is not well characterized.
We developed an abomasal oligofructose infusion model using a single pulse dose to mimic the increase in postruminal fermentation observed with SARA without altering rumen fermentation (Mainardi et al., 2011) . ABSTRACT: Two studies were conducted to evaluate the effects of abomasal carbohydrate infusion on nutrient digestibility and fecal measures. In Exp. 1, 5 Holstein steers were assigned to a Latin square with 1-wk periods and were abomasally infused on a single day at the end of each period with water alone, a single pulse dose of water with 1 g/kg BW oligofructose or cornstarch, or 4 pulse doses of water with 0.25 g/ kg BW oligofructose or cornstarch administered every 6 h. Total tract nutrient digestibility was not affected by treatment except for a tendency for a decrease in starch digestibility in response to the 1 g/kg BW dose of cornstarch (P < 0.10). Compared with the control, both oligofructose and starch infusions caused similar decreases in fecal pH (P < 0.05) and increases in fecal short-chain fatty acids (P ≤ 0.01) measured 12 h after the first infusion, with the single 1 g/kg BW infusions causing a greater magnitude of pH change compared with the four 0.25-g/kg BW infusions (P < 0.01). All treatments increased concentration of fecal lipopolysaccharide compared with the control for at least 1 time point following the infusion (P < 0.05), with a greater increase observed for the 0.25 g/kg BW infusions of oligofructose compared with the other treatments (P < 0.05). Results of Exp. 1 indicate that both oligofructose and cornstarch infusions increased carbohydrate fermentation in the intestines and can be used as a method to evaluate the impact of excessive intestinal fermentation on intestinal health. In Exp. 2, 6 Holstein steers received abomasal pulse doses of 0 (control) or 10 g/d live Saccharomyces cerevisiae var. boulardii (SB) according to a crossover design with 18-d periods. Abomasal infusions of 4 pulse doses of 0.25 g/kg BW oligofructose administered every 6 h were conducted on d 16 of each period. During the baseline period prior to the oligofructose challenge, there were no effects of SB on fecal measures except for an increase in apparent total tract NDF digestibility (P < 0.05), suggesting that SB increased intestinal fiber fermentation. During the oligofructose challenge, SB increased fecal score (P = 0.03) and tended to reduce fecal short-chain fatty acids (P = 0.10). Results of Exp. 2 suggest that abomasal SB modestly stabilized the intestinal environment during increased carbohydrate fermentation.
However, the single pulse dose nature of that model caused more dramatic changes in fecal composition than typically observed with SARA (Mainardi et al., 2011) . Additionally, although oligofructose infusion delivered a precise amount of fructans to intestinal microbes, starch is the substrate primarily responsible for the hindgut effects of SARA (Hall, 2002; Li et al., 2012) . Therefore, abomasal starch infusion may be a better model of increased intestinal fermentation that accompanies SARA. The objectives of Exp. 1 were to compare the effects on fecal measures of oligofructose or cornstarch delivered into the abomasum as either a single pulse dose or 4 pulse doses. Additionally, Saccharomyces cerevisiae var. boulardii is a direct fed microbial used in monogastrics that leads to beneficial microbiome shifts and improved intestinal health (Everard et al., 2014; Feizizadeh et al., 2014) . The objectives of Exp. 2 were to evaluate whether abomasal S. cerevisiae var. boulardii would attenuate the response to an abomasal oligofructose challenge.
MATERIALS AND METHODS

Animals and Treatments
All procedures were approved by the University of Delaware Agricultural Animal Care and Use Committee. Ruminally cannulated Holstein steers were individually housed in 2.4 by 4.6 m pens with automatic waterers. Steers were fed once daily a lactating cow ration (Table 1) restricted to 1.5% BW, and steers always consumed all feed provided. Steers were restricted fed to prevent excessive weight gain and to prevent differences in intake among treatments. Before the start of each experiment, each steer was fitted with an abomasal infusion line (Gressley et al., 2006) . Abomasal infusions were rigorously mixed in a plastic bottle and administered using a veterinary stomach pump (Nasco, Fort Atkinson, WI). Experiment 1. Steers (n = 5; 947 ± 33 kg and approximately 3.5 yr old) were assigned to a 5 × 5 Latin square experimental design with 7-d periods. Treatments were administered on d 6 of each period and consisted of a control with no carbohydrate infusion (CON); 1 g/ kg BW oligofructose administered as a single infusion at 0 h (OL1); 1 g/kg BW starch administered as a single infusion at 0 h (ST1); 1 g/kg BW oligofructose administered as 0.25 g/kg BW at 0, 6, 12, and 18 h (OL4); and 1 g/kg BW starch administered as 0.25 g/kg BW at 0, 6, 12, and 18 h (ST4). Treatments were accomplished by suspending no carbohydrate, cornstarch (Argo Food Companies Inc., Memphis, TN), or oligofructose (Beneo P95; Orafti Active Food Ingredients, Tienen, Belgium) in 1.6 L water. Abomasal infusions consisted of water only or water plus carbohydrate, depending on treatment, and occurred immediately after feeding (0 h) and at 6, 12, and 18 h thereafter. Experiment 2. Steers (n = 6; 900 ± 76 kg and approximately 3 yr old) were assigned to a crossover experimental design with 18-d periods. Treatments were administered into the abomasal infusion line via a 60-mL catheter-tip syringe twice daily in 50 mL water (100 mL/d) immediately after feeding (0 h) and 6 h later and consisted of a control with water infusion only (WATER) or 5 g (10 g/d) S. cerevisiae var. boulardii CNCM I-1079 (SB; Levucell SB20; label concentration of 2.0 × 10 10 cfu/g; measured concentration of 2.6 × 10 10 cfu/g; Lallemand Animal Nutrition, Milwaukee, WI) suspended in the infused water. On d 16 of each period, all animals were abomasally infused at 0, 6, 12, and 18 h with 1.6 L water containing 0.25 g/kg BW of oligofructose.
Feed Sampling and Analyses
For both experiments, individual feed components were collected once weekly and dried for 48 h at 60°C in a forced-draft oven, with results used to adjust the total mixed ration (TMR) for DM fluctuations. Total mixed ration samples were collected twice weekly, dried for 48 h at 60°C in a forced-draft oven, and composited by week. Weekly TMR composite samples were ground through a 2-mm screen using a Wiley Mill (A. H. Thomas Co., Philadelphia, PA). Representative subsamples were sent to Cumberland Valley Analytical Services (Hagerstown, MD) for analysis of ADF (method 973.18; AOAC, 2006) and starch (Hall, 2009) . Remaining samples were analyzed in house for N, NDF, ash, and indigestible NDF (iNDF). Nitrogen was measured using an Elementar Vario Max CN Analyzer (Elementar Americas Inc., Mt. Laurel, NJ) and NDF was determined using sodium sulfite and α-amylase (Goering and Van Soest, 1970) using the Ankom 200 Fiber Analyzer (Ankom Technology, Macedon, NY). Ash content was measured following 5 h at 600°C in a muffle furnace. Indigestible NDF was determined after 120 h in vitro incubation in a Daisy II incubator (Ankom Technology) using the Goering and Van Soest (1970) method with modifications as described by Klingerman et al. (2009) . In both experiments, rumen fluid for iNDF determination was collected from 2 lactating cows being fed the experimental ration and was replaced with fresh fluid following 60 h of incubation.
Fecal Sampling and Analyses
Experiment 1. Fecal grab samples (approximately 300 g) were collected every 6 h during the last 2 d of each period, beginning at 0 h (the time of the first abomasal infusion) and ending at 42 h (24 h after the last abomasal infusion). The fecal score was assessed based on consistency: 1 = watery to 5 = solid (Hulsen, 2006) . A subsample of 20 ± 0.5 g of feces was mixed with 20 mL of distilled water and the pH was measured using a portable pH meter (Extech Instruments, Waltham, MA) immediately after collection. The remaining feces was subsampled and frozen for analysis of DM, nutrient composition, short-chain fatty acids (SCFA), and endotoxin. Specifically, a 100-g subsample of feces was stored at -20°C until analysis of DM and nutrient composition, a 25 ± 0.5-g subsample was mixed with 10 mL of 2% H 2 SO 4 and stored at -20°C until SCFA analysis, and a 1-g subsample was stored at -20°C in an endotoxin-free microcentrifuge tube until endotoxin analysis.
For DM and nutrient composition, fecal samples were thawed and dried for 48 h at 60°C in a forceddraft oven. Fecal samples were then composited by steer and period and ground through a 2-mm screen using a Wiley Mill. Composited samples were analyzed for NDF, N, starch, ash, and iNDF as described for the TMR samples. Indigestible NDF in feeds and feces was used as a marker to calculate fecal output and apparent total tract nutrient digestibility (Oba and Allen, 2003) . Nutrients provided in the infusates were included in the digestibility calculations but amounts supplied by the infusates were divided by 2. This accounted for abomasal infusions being conducted only on d 6 whereas fecal samples were composited from both d 6 and 7.
Fecal SCFA were determined as described by Mainardi et al. (2011) . Briefly, 25 ± 0.5 g of feces were acidified, stored at -20°C, and analyzed using HPLC using procedures described by Muck and Dickerson (1988) .
The endotoxin concentrations of the fecal samples were evaluated using a commercial chromogenic end point limulus amebocyte lysate (LAL) assay (QCL-1000 Endpoint Chromogenic LAL Assay; Lonza Ltd., Basel, Switzerland) based on the procedures of Levin and Bang (1964) . Samples were thawed and centrifuged at 10,000 × g for 30 min at 21°C, the supernatant was diluted 1:100 in endotoxin-free water, and the diluted supernatant was passed through a 0.22-μm sterile filter and stored at -20°C in endotoxin-free glass vials until the LAL assay was performed. For the LAL assay, samples were further diluted 10-fold in endotoxin-free water and treated with a 1:1 ratio of diluted sample to β-1,3 glucan blocker (β-G-Blocker; Lonza Ltd.). After treatment with the β-1,3 glucan blocker, samples were analyzed for endotoxin according to manufacturer's instructions. Standards and unknowns were assayed in duplicate and unknowns were further diluted as needed, resulting in final dilutions of unknown samples of 1:2,000, 1:10,000, 1:50,000, or 1:500,000. Intra-assay and interassay CV both averaged 7.8%. Experiment 2. Fecal grab samples (approximately 300 g) were collected every 6 h on d 15 through 16 of each period, representing from 24 h before the first abomasal oligofructose dose (-24 h) through 24 h after the first abomasal oligofructose dose (+24 h). Fecal grab samples were also collected on d 17 at +30, +36, and +48 h after the first abomasal oligofructose dose.
Fresh fecal samples were assessed for consistency score and pH as described for Exp. 1. Subsamples of feces were acidified and stored at -20°C until analyzed for SCFA as described for Exp. 1, except that only lactate, acetate, propionate, and butyrate were quantified. Approximately 200 g of feces was stored at -20°C for later DM and nutrient analysis. Samples were thawed, dried, and ground as described for Exp. 1, but instead of compositing across the entire period, samples within steer and period were composited to represent baseline (-24, -18, -12 , and -6 h relative to the first oligofructose dose), challenge d 1 (0, +6, +12, +18, and +24 h relative to the first oligofructose dose), and challenge d 2 (+30, +36, and +48 h relative to the first oligofructose dose) time periods. Each composite fecal sample was analyzed for NDF, N, starch, ash, and iNDF as described for Exp. 1, and apparent total tract nutrient digestibility was calculated for the prechallenge, challenge, and postchallenge periods including nutrients provided by the infusates during each of those periods. A portion of each of the fecal grab samples collected during the prechallenge period (-24, -18, -12 , and -6 h relative to the first oligofructose dose) was also used to measure fecal yeast concentrations. For fecal yeast measurement, 30 g of feces was stored at 4°C for approximately 6 h before homogenizing for 1 min in a blender (Waring Products, New Hartford, CT) in 270 mL of a peptone solution (1 g/L pancreatic casein peptone and 8.5 g/L NaCl). The homogenate was filtered through cheesecloth and serially diluted in peptone solution. Dilutions of 10 -3 and 10 -4 were pipetted onto yeast enumerating film (Petrifilm; 3M Microbiology Products, St. Paul, MN) and incubated at 30°C for 72 h, and colonies were counted.
Statistical Analyses
Experiment 1. Data were analyzed using the MIXED procedure of SAS (SAS Inst. Inc., Cary, NC). Endotoxin concentrations were right skewed; therefore, endotoxin data were log 10 transformed before analysis. Repeated measures (fecal score, pH, SCFA, DM, and endotoxin) were analyzed using a model that included the fixed effects of treatment, hour, period, and the interactions of treatment × hour and period × hour. Steer and steer × period × treatment were included in the model as random effects. Hour was analyzed as a repeated measure with steer × period × treatment as the subject of the repeated statement. A first order autoregressive covariance structure was used as it provided the best fit based on the Akaike information criterion. Pairwise comparisons among treatment means were evaluated using a Tukey's studentized range test. Differences among treatments at each hour were evaluated using the splice option and a Tukey's adjustment. Digestibility results were analyzed using a model containing the fixed effects of treatment and period and the random effect of steer. Significance was declared at P ≤ 0.05 and trends were declared at P ≤ 0.10. Experiment 2. Results were analyzed using the MIXED procedure of SAS. For fecal DM, score, pH, and SCFA, data collected the day before the oligofructose challenge (baseline period; samples at -24, -18, -12, and -6 h) were analyzed independently from data collected immediately prior to, during, and following the oligofructose infusions (challenge period; samples at 0, 6, 12, 18, 20, 24, 30, 36, and 48 h) . Those models included the fixed effects of treatment, treatment sequence, hour, period, and the interaction of treatment × hour. Steer within treatment sequence was included in the model as a random effect. Hour was analyzed as a repeated measure with steer within sequence by treatment as the subject. A first order autoregressive covariance structure was used as it provided the best fit based on the Akaike information criterion. Differences among treatments at each hour were evaluated using the pdiff option. Total tract digestibility was analyzed using the previously described model, except that all data were analyzed together in the same model and day (baseline, challenge d 1, and challenge d 2) replaced hour in the model. Significance was declared at P ≤ 0.05 and trends declared at P ≤ 0.10.
RESULTS
Experiment 1
Nutrient Digestibility. Steers were feed restricted to 1.5% BW diet DM/d, and steers always consumed all feed provided in both experiments. Apparent total tract nutrient digestibility results from Exp. 1 are presented in Table 2 . Digestibilities of DM, OM, NDF and CP were unaffected by treatment, but starch digestibility tended to be lower for the ST1 treatment compared with the CON and ST4 treatments (P < 0.10). In Exp. 1, digestibility was calculated over the combined challenge and postchallenge periods, which did not allow for measuring effects of treatment over time on digestibility.
Fecal DM, Score, and pH. Effects of treatments on fecal DM, score, and pH in Exp. 1 are presented in Table 3 . Main effects of treatment and interactions of treatment and time were observed for fecal score and pH (P < 0.01), and the effect of time was significant for all 3 measures (P < 0.001). The effect of time on fecal DM was due to higher DM at 12 and 36 h compared with other times (data not shown). The interaction of treatment × time on fecal score was driven by reduced fecal score for the OL1 treatment compared with all other treatments at both 6 and 12 h (P < 0.01) and reduced fecal score for the OL4 treatment compared with all other treatments except the CON treatment at 30 h (P < 0.05; Fig. 1 ). For fecal pH, at 6 h, the OL1 treatment was lower than both the CON and the ST1 treatments (P < 0.05; Fig. 1) . At 12 h, all carbohydrate infusions reduced pH compared with the CON treatment (P < 0.01), and the magnitude of the reduction was dependent on dosing schedule but independent of substrate. The lowest pH was observed for the OL1 and ST1 treatments (5.97 and 5.95, respectively, compared with 6.98 for the CON treatment; P < 0.001) and an intermediate pH was observed for the OL4 and ST4 treatments (6.53 and 6.61, respectively, compared with 6.98 for CON; P < 0.05). The only other differences in pH were observed at 18 h, when the OL4 treatment was lower than both the CON and the OL1 (P < 0.05) treatments.
Fecal Short-Chain Fatty Acids. In Exp. 1, treatment did not affect fecal acetate concentration (P = 0.95), but all other SCFA were either affected by treatment or treatment × time interactions (P < 0.05; Table 3 ). The treatment effects on fecal pH were mirrored by changes in fecal SCFA, and concentration of total SCFA was elevated in all treatments compared with the CON treatment at 12 h (P < 0.01; Fig. 1 ). The increase in total SCFA at 12 h was due to increases in individual SCFA that varied by treatment. Specifically, lactate was greater than the CON treatment at 12 h for the OL1 (P < 0.001), ST1 (P = 0.001), and ST4 treatments (P = 0.09). Propionate was greater than the CON treatment for both the ST1 (P < 0.001) and the OL4 (P = 0.002) treatments, and butyrate was greater than the CON treatment for the ST1 (P < 0.001) and ST4 (P < 0.001) treatments.
In addition to the differences from the CON treatment described above, the OL1 treatment had greater lactate than all other treatments at 12 h (P < 0.001) and lactate for the ST1 treatment was greater than that for the OL4 treatment at 12 h (P < 0.001). For propionate, the OL4 treatment was elevated above all other treatments at 18 (P < 0.05) and 24 h (P < 0.001) and tended to be greater than the CON, OL1, and ST1 treatments at 30 h (P < 0.10). At 12 h, fecal propionate was greater in the ST1 treatment compared with both the OL1 and the ST4 treatments (P < 0.05). Differences in response to the carbohydrate infusions were also observed for butyrate at 12 h, when both the ST1 and ST4 treatments caused an Means within a row with unlike superscripts tend to differ (P < 0.10).
1 Oligofructose (97.4% DM, 100% OM, 0.70% starch, 0.25% NDF, 0.25% CP, and 0.00% indigestible NDF) or starch (88.95% DM, 99.75% OM, 98.15% starch, 0.55% NDF, 0.55% CP, and 0.00% indigestible NDF) was administered into the abomasum on d 6 of each period and were included in digestibility calculations.
2 Fecal samples were collected every 6 h on d 6 and 7 of each period and composited. Fecal output was estimated using indigestible NDF as a marker. Digestibility was calculated including nutrients from abomasal infusates averaged over d 6 (abomasal infusions) and 7 (no abomasal infusions).
3 Treatments were abomasal infusions on d 6 of water only (control with no carbohydrate infusion [CON]); 1 g/kg BW oligofructose administered as a single infusion at 0 h (OL1); 1 g/kg BW oligofructose administered as 0.25 g/kg BW at 0, 6, 12, and 18 h (OL4); 1 g/kg BW starch administered as a single infusion at 0 h (ST1); or 1 g/kg BW starch administered as 0.25 g/kg BW at 0, 6, 12, and 18 h (ST4). a-c Means within a row with unlike superscripts differ (P < 0.05).
1 Treatments were abomasal infusions on d 6 of water only (control with no carbohydrate infusion [CON]); 1 g/kg BW oligofructose administered as a single infusion at 0 h (OL1); 1 g/kg BW oligofructose administered as 0.25 g/kg BW at 0, 6, 12, and 18 h (OL4); 1 g/kg BW starch administered as a single infusion at 0 h (ST1); or 1 g/kg BW starch administered as 0.25 g/kg BW at 0, 6, 12, and 18 h (ST4).
2 Fecal samples were collected every 6 h on d 6 and 7. Figure 1 . Effect of pulse dose abomasal infusion of water alone (-○-), 1 g/kg BW oligofructose infused at 0 h (--□--), 0.25 g/kg BW oligofructose infused at 0, 6, 12, and 18 h (--■--), 1 g/kg BW cornstarch infused at 0 h (· ·∆· ·), or 0.25 g/kg BW cornstarch infused at 0, 6, 12, and 18 h (· ·▲· ·) on fecal score, fecal pH, fecal concentrations of organic acids, and fecal endotoxin. Total short-chain fatty acids (SCFA) is the sum of lactate, acetate, propionate, butyrate, isobutyrate, valerate, and isovalerate. Endotoxin data were log 10 transformed before analysis to achieve homogeneity of residual variance. Error bars represent SED for the interaction of treatment and time. EU = endotoxin unit.
increase in butyrate compared with the OL1 and OL4 treatments (P < 0.01). For isobutyrate, the OL1 treatment was lower than all other treatments at 6 h (0.06 vs. 1.16 to 1.50 mM; P < 0.01; data not shown). In addition, the OL4 treatment tended to have lower isobutryate compared with the CON treatment at 18 h (0.13 vs. 1.06; P = 0.06; data not shown), was significantly lower than both the CON and the ST4 treatments at 24 h (0.35 vs. 1.59 and 0.98, respectively; P < 0.05; data not shown), and was significantly lower than both the CON and the OL1 treatments at 42 h (0.39 vs. 1.33 and 1.23, respectively; P < 0.05; data not shown). Fecal concentrations of valerate were higher for the OL4 treatment than all other treatments at both 30 (0.24 mM) and 36 h (0.33 mM), when valerate concentrations in the other treatments ranged from 0.00 to 0.08 mM (P < 0.05; data not shown). For isovalerate, all treatments were reduced or tended to be reduced compared with the CON treatment at 24 h (0.00 to 0.07 vs. 0.33 mM for the CON treatment; P < 0.10; data not shown). In addition, isovalerate concentrations at 30 h were elevated or tended to be elevated for the OL4 treatment compared with all other treatments (0.58 vs. 0.00 to 0.31 mM; P < 0.10; data not shown).
Fecal Endotoxin. Fecal endotoxin was evaluated only in Exp. 1. Across all times, fecal endotoxin was greatest for the OL4 treatment, lowest for the CON treatment, and intermediate for the OL1 and ST1 treatments (P < 0.001 for treatment; Table 3 ). The ST4 treatment was numerically greater than the CON treatment and not significantly different from the CON, OL1, or ST1 treatments (P > 0.10). Fecal endotoxin concentration measured as endotoxin units per milliliter for the OL1, ST1, and ST4 treatments were 2.2 to 3.0 times that of the CON treatment and the OL4 treatment was 8.7 times that of the CON treatment. Compared with the CON treatment, fecal endotoxin increased at 12 and 18 h for the OL1 treatment; at 6, 12, and 18 h for the ST1 treatment; and at 12 through 36 h for the OL4 treatment (P < 0.05; Fig. 2 ). The maximum differences from the CON treatment for both the OL1 and the ST1 treatments were observed at 12 h (P < 0.001), when endotoxin concentrations were 56 times and 19 times that of the CON treatment, respectively. For the OL4 treatment, the maximum difference from the CON treatment occurred at 24 h (P < 0.001), when fecal endotoxin was 57 times that of the CON treatment.
Experiment 2
Nutrient Digestibilities. In Exp. 2, apparent digestibilities were determined 1 d before the challenge (baseline), the day of the challenge (challenge d 1), and the day following the challenge (challenge d 2). The oligofructose infusion reduced DM and OM digestibility (day effect, P = 0.01 and P = 0.02, respectively; Table 4 ). For both DM and OM, apparent digestibility during the baseline period and challenge d 1 were greater than on challenge d 2 (P = 0.02). An interaction of treatment and day tended to occur for NDF digestibility (P = 0.07), with a decrease over time for SB but not the WATER treatment. Digestibility of NDF during the baseline period was greater than on challenge d 2 (P = 0.03) and tended to be greater than on challenge d 1 (P = 0.07). Furthermore, NDF digestibility was greater for cows infused with SB during the baseline period compared with all other treatment and time combinations (P < 0.05).
Fecal DM, Score, and pH. In Exp. 2, only 19% of fecal samples contained countable yeast colonies and fecal yeast concentration was not affected by treatment (data not shown). Effects of the SB treatment on fecal DM, score, and pH were independently evaluated during the baseline Figure 2 . Effect of twice daily abomasal infusion of 50 mL water only (─○─) or 50 mL water containing 5 g (10 g/d) Saccharomyces cerevisiae var. boulardii (--•--) on fecal score (1 = watery to 5 = firm), fecal pH, and organic acids (sum of lactate, acetate, propionate, and butyrate). Oligofructose (0.25 g/kg BW) was infused at 0, 6, 12, and 18 h, and baseline period data (-24 to -6 h) were analyzed separately from challenge period data (0 to 48 h). Error bars represent SED for the interaction of treatment and time. SCFA = short-chain fatty acids.
and challenge periods and results are presented in Table 5 . During the baseline period before the oligofructose challenge, none of the fecal measures were affected by abomasal infusion of SB, and interactions of treatment and time were not observed. Fecal score tended to be affected by time (P = 0.06) and fecal pH was affected by time (P = 0.001; Fig. 2 ). During the challenge period, time affected both fecal score and pH (P < 0.001), with a decline in both measures in response to the challenge (Fig. 2) . Fecal pH at 12 h was lower than at all other time points (P < 0.05) and pH at 24 h was greater than at all other times (P ≤ 0.05). The effect of time on fecal score during the challenge period was due to reduced fecal score at 18 and 24 h compared with all other time times (P < 0.05). Abomasal SB increased fecal score compared with the WATER treatment (P = 0.03), with the greatest difference between treatments observed at 30 h (Fig. 2) .
Fecal Short-Chain Fatty Acids. In Exp. 2, SB did not affect any of the fecal SCFA measured during the baseline period, and no interactions of treatment × time were observed (Table 5) . During the challenge period, there was a tendency for reduced total fecal SCFA in steers on the SB treatment compared with steers on the WATER treatment (P = 0.10). Although the interaction of treatment and time was not significant, this treatment effect was largely driven by differences at 12 (90.9 vs. 67.7 mM; P = 0.04) and 18 h (95.6 vs. 70.2 mM; P = 0.03) following the challenge (Fig. 2) . All measured SCFA were affected by time during the challenge period (P < 0.001) due to an increase in response to the abomasal oligofructose infusions. The greatest concentrations of acetate and butyrate were observed at 12 h (54.4 and 5.8 8 mM, respectively), lactate was greatest at 18 h (12.2 mM), and propionate was greatest at 24 h (19.5 mM; data not shown). Total SCFA decreased between 0 and 6 h (P = 0.05), but SCFA concentrations at 12 and 18 h were greater than at either 0 or 6 h (P ≤ 0.03; Fig. 2 ).
DISCUSSION
The objective of Exp. 1 was to compare the model developed by Mainardi et al. (2011) to a model using a single abomasal infusion of starch and to models using more frequent but smaller pulse doses of starch or oligofructose. Subacute ruminal acidosis is associated with an increased flow of rapidly fermentable carbohydrates to the intestines, and it has been suggested that some of the negative consequences of SARA on animal health may be mediated by excessive carbohydrate fermentation in the intestines (Plaizier et al., 2008; Gressley et al., 2011; Li et al., 2012) . In a previous study, we developed a model using abomasal infusion of a soluble fiber (oligofructose) to induce changes in intestinal fermentation similar to those seen with SARA without concurrent changes in rumen fermentation (Mainardi et al., 2011) . We previously chose oligofructose because it is not digestible by mammalian enzymes and therefore provides a precise amount of highly fermentable substrate to intestinal microbes. However, starch, not oligofructose, is the primary fermentable carbohydrate arriving in the intestines during SARA (Li et al., 2012) and would cause different changes in the intestinal microbiome compared with oligofructose. Furthermore, the single pulse dose of oligofructose used in our previous work likely increased osmotic pressure in intestinal digesta, so in the current work, we compared the single pulse dose with multiple smaller pulse doses of starch and Means within a row with unlike superscripts differ (P < 0.05).
1 Oligofructose (97.4% DM, 100% OM, 0.70% starch, 0.25% NDF, 0.25% CP, and 0.00% indigestible NDF) was administered into the abomasum on d 1 of the challenge period and was included in challenge d 1 digestibility calculations.
2 Treatments were twice daily abomasal infusion of 50 mL water only (control with water infusion only [WATER]) or 5 g (10 g/d) Saccharomyces cerevisiae var. boulardii (SB; Levucell SB20; label concentration of 2.0 × 10 10 cfu/g; measured concentration of 2.6 × 10 10 cfu/g; Lallemand Animal Nutrition, Milwaukee, WI) suspended in the infused water.
3 DM digestibility on the baseline day (67.3%) and challenge d 1 (67.1%) was higher than on challenge d 2 (65.1%).
oligofructose. Our periods were short, with 5 d of recovery at the beginning of each period before carbohydrate infusion. We expected this to allow adequate recovery time because fecal measures returned to normal within 2 d following a similar challenge in our previous work (Mainardi et al., 2011) and in the present study (Fig. 1) . It is possible, however, that there may have been some carryover between periods, but we do not expect this to impact interpretation of treatment differences. The objective of Exp. 2 was to evaluate the effect of abomasal infusion of S. cerevisiae var. boulardii on measures of hindgut fermentation both before and following the OL4 oligofructose challenge model used in Exp. 1. We hypothesized that the SB treatment would stabilize microbial shifts and lessen the severity of changes in fecal composition in response to the abomasal oligofructose challenge. In human children, S. cerevisiae var. boulardii is clinically administered to reduce the severity and incidence of diarrhea (Feizizadeh et al., 2014) . In monogastric production and laboratory animals, S. cerevisiae var. boulardii feeding leads to beneficial shifts in the intestinal microbiome (Everard et al., 2014) , increased mucosal integrity (Rajput et al., 2013) , and improved response to an intestinal pathogen challenge (Munyaka et al., 2012; Buntyn et al., 2014) . We chose to infuse S. cerevisiae var. boulardii into the abomasum to prevent degradation in the rumen. Fecal yeast recovery was low regardless of treatment, suggesting that most of the infused S. cerevisiae var. boulardii was degraded within the digestive tract. Blehaut et al. (1989) recovered less than 1% of live S. cerevisiae var. boulardii in feces of supplemented humans and rats. Despite lack of survival in the digestive tract, the benefits of S. cerevisiae var. boulardii are proposed to be due to protection of the intestinal mucosa, inhibition of pathogen growth and translocation, and modification of intestinal fermentation patterns (Buts and De Keyser, 2006; Feizizadeh et al., 2014) .
Subacute ruminal acidosis typically depresses fiber digestibility (Plaizier et al., 2008) , which would result in reduced total tract digestibility of DM, OM, and NDF. Although this effect is mostly due to reduced fiber digestion in the rumen, reduced fiber digestion in the intestines may also play a role. In previous work, we found that abomasal infusion of pectin or oligofructose reduced total tract apparent nutrient digestibility in lactating cows Armentano, 2005, 2007) . We expected to see reduced nutrient digestibility as a result of the abomasal carbohydrate infusions. Part of these expected differences may be due to increased load of fermentable carbohydrates reaching the intestines. Based on nonstructural carbohydrate intake of the steers used in the present experiments and ileal digestibilities found by Callison et al. (2001) , we expect that we roughly doubled the amount of nonstructural carbohydrates reaching the large intestine for animals infused with oligofructose. For animals infused with starch, the load may have been doubled or less than doubled, depending on how much was enzymatically digested in the small intestines.
No differences in digestibility were observed in Exp. 1 except for a tendency for decreased starch digestibility for the ST1 treatment compared with the CON treatment (P < 0.10). This suggests that the single pulse dose of cornstarch overwhelmed the capacity for small and large intestinal degradation whereas starch provided in the 4 pulse doses of the ST4 treatment was completely degraded in the intestines. Reynolds et al. (2001) found that continuous abomasal infusion of 1.2 kg/d wheat starch (1.8 g/kg BW) in lactating cows decreased starch digestibility without affecting digestibility of other nutrients. Although continuously administered, the dose used by Reynolds et al. (2001) was nearly twice what we used, suggesting that less frequent dosing schedules and increased starch infusion amounts both negatively impact starch digestibility.
In Exp. 1, we used composite fecal samples collected over the entire challenge and postchallenge period. It is possible that compositing may have masked subtle treatment differences in digestibility because the treatments were administered over an 18-h period whereas fecal samples represented a 42-h period. Therefore, in Exp. 2, we composited fecal samples separately for each day: before the challenge (baseline), the day of the challenge (challenge d 1), and the day following the challenge (challenge d 2). Digestibilities of DM, OM, and NDF were lower on challenge d 2 compared with the baseline (P < 0.05; Table 4 ), suggesting that nutrient digestibility in the intestines was reduced by the increased flow of fermentable carbohydrates. Alternatively, increased fecal bacteria flow or greater passage rates following the infusion may have contributed to reduced apparent digestibility. We expected the SB treatment in Exp. 2 to reduce the oligofructose-induced decrease in nutrient digestibility as would have been evidenced by an interaction of treatment and time. However, the only treatment × time interaction observed was a tendency for an effect on NDF digestibility (P = 0.07), but this was due to a benefit of SB during only the baseline period. The ability of yeast supplements to improve carbohydrate digestion in the rumen has been known for quite some time (Martin and Nisbet, 1992) . Although little work has been done specifically to evaluate the effects of S. cerevisiae var. boulardii on digestion, Oeztuerk et al. (2005) found that either live or killed S. cerevisiae var. boulardii increased in vitro rumen VFA concentrations and microbial protein yields. Because S. cerevisiae var. boulardii was infused into the abomasum, the baseline period increase in NDF digestibility suggests that yeast supplement increased intestinal NDF digestion. This benefit was not maintained during the oligofructose challenge, suggesting that those microbial populations responsible for the enhanced intestinal NDF digestion were lost in response to the challenge.
Increased carbohydrate fermentation in the intestines can lead to increased fecal SCFA and endotoxin concentrations and reduced fecal pH, DM, and score (Mainardi et al., 2011; Li et al., 2012) . The primary objective of Exp. 1 was to compare the effects of the different abomasal carbohydrate challenges on these measures of fermentation. The lack of treatment effect on fecal DM was unexpected. Diarrhea is an indicator of SARA (Hall, 2002) , and we previously found that a single pulse dose of abomasal oligofructose decreased fecal DM by 2.6 percentage units 6 h following the challenge (Mainardi et al., 2011) . Similar to our previous observations, the single pulse dose of oligofructose in the OL1 treatment decreased the fecal score (P = 0.01; Fig. 1 ), but it did not decrease fecal DM (P = 0.17). Furthermore, splitting the oligofructose into 4 doses (the OL4 treatment) caused a much less dramatic effect on the fecal score, with a significant drop compared with other treatments observed only at 30 h (P < 0.05), suggesting that the dosing schedule resulted in a much less severe osmotic challenge in the intestines than the OL1 treatment. Neither starch infusion impacted fecal score (P > 0.10). This is in contrast to Bissell (2002) , who found that abomasal infusions of a much larger amount of starch (5 g/kg BW) in cows dramatically decreased fecal DM and fecal score.
Despite the differences in their effects on fecal DM and score, both substrates similarly depressed fecal pH at 12 h (P < 0.05), with the single pulse dose producing the greatest reduction (6.0 for both the OL1 and the ST1 treatments vs. 7.0 for the CON treatment; P < 0.001) and the multiple pulse doses producing an intermediate decrease (6.5 for the OL4 treatment and 6.6 for the ST4 treatment; P < 0.05; Fig. 1 ). Similarities in the pH depression response to either starch or oligofructose suggest that a substantial proportion of infused starch bypassed intestinal digestion and was fermented in the large intestine to an extent similar to oligofructose. The lesser decline in pH for the ST4 and OL4 treatments compared with the ST1 and OL1 treatments indicates a less dramatic increase in fermentation by splitting the infusion into 4 doses. For the ST4 treatment, the split dose may have allowed for a larger extent of small intestinal starch digestion compared with the ST1 treatment. Additionally, for both the ST4 and OL4 treatments, the split dose provided less amount of substrate to intestinal microbes following each dose, resulting in a lesser increase in fermentation compared with the ST1 and OL1 treatments, respectively. Mainardi et al. (2011) compared the CON and OL1 treatments in an independent study and found that fecal pH declined, although the magnitude of the difference between the CON and OL1 treatments was less than that in the present study (7.0 for the CON treatment vs. 6.5 for the OL1 treatment at 12 h after infusion). The difference in the magnitude of the pH change between the 2 studies may have been due to the ad libitum feeding in the trial of Mainardi et al. (2011) compared with restricted feeding in the current study. Reynolds et al. (2001) observed that fecal pH decreased from 6.64 to 6.26 in response to abomasal wheat starch infusion.
In Exp. 1, treatment or the interaction of treatment and hour affected all SCFA evaluated except for acetate. All treatments increased fecal SCFA concentration at 12 h (P < 0.01), although changes in individual SCFA were affected by substrate and dosing schedule. At 12 h, SCFA concentrations were 46.7, 84.5, 93.4, 73.8, and 72 .8 mM for the CON, OL1, ST1, OL4, and ST4 treatments, respectively. Again, the similar increases in response to the infused substrates suggest that both oligofructose and starch were degraded to similar extents by intestinal microbes. Interestingly, the dramatic increase in fecal lactate observed for the OL1 treatment at 12 h did not correspond to a decreased pH compared with the ST1 treatment, as the increase in other fecal SCFA for the ST1 treatment resulted in a similar pH decline. Krause et al. (2009) similarly noted an elevation in lactate levels in response to a SARA challenge but suggested that the primary cause of ruminal pH depression was the increase in other SCFA concentrations. Li et al. (2012) showed that a decrease in rumen pH following a SARA challenge was associated with increased total VFA concentrations. Results from our study suggest that fecal pH or total SCFA measured 12 h after feeding might be of use in diagnosing problems with excessive intestinal fermentation.
In Exp. 1, fecal endotoxin concentration was increased by all treatments compared with the CON treatment (P < 0.10), although contrary to some of the other fecal measures, the increase in response to the starch infusions was less than the increase in response to the oligofructose infusions. Some lysis of live bacteria likely occurred during sample processing and storage, which may have resulted in overestimates of free fecal endotoxin. We expect, however, that this would be consistent across treatments and not impact our interpretation of treatment differences. Free rumen endotoxin increases as the amount of concentrate in the diet increases (Gozho et al., 2005 (Gozho et al., , 2006 Emmanuel et al., 2008; Khafipour et al., 2009) , and the magnitude of this increase has been correlated with the degree of systemic inflammation (Zebeli et al., 2012) . Increased free endotoxin combined with reduced pH in response to SARA could cause gastrointestinal damage and lead to translocation of endotoxin and other inflammatory compounds across the rumen or intestinal epithelium (Khafipour et al., 2009 ). Similar to Li et al. (2012) , who noted an increase in cecal endotoxin in response to a grain-based SARA challenge, our results indicate that increased postruminal fermentation of either oligofructose or starch increased endotoxin release in the intestines.
Although the goal of Exp. 2 was not to compare baseline and challenge periods, fecal pH and SCFA concentrations during the challenge period in WATER steers were similar to those observed for the OL4 treatment in Exp. 1. This suggests that 4 abomasal pulse doses of 0.25 g/kg BW oligofructose every 6 h similarly affected steers in both experiments. We expected the SB treatment to lessen the magnitude of the changes over time in fecal measures compared with the WATER treatment during the challenge period. Although most measures were unaffected, there was a tendency for total SCFA to be reduced for SB compared with WATER-treated steers (P = 0.10) due to differences at 12 and 18 h (Fig.  2) . This, combined with a more rapid increase in fecal score following the challenge (Table 5 ; Fig. 2) , suggests that the SB treatment modestly stabilized the intestinal environment following the oligofructose challenge.
One limitation of the experiments conducted was the short duration of the abomasal carbohydrate infusion, either a single dose or multiple pulse doses within a 24-h period. Our goal in using this model was to cause a dramatic swing in intestinal fermentation that might result from a single acidosis bout. In practice, rations that cause excessive fermentation in the hindgut would likely be fed for extended periods of time and result in adaptations by the animal and gut microflora that might dampen or change some of the effects observed in these studies. Future studies could use longer-term carbohydrate infusions to evaluate changes in fecal composition following intestinal adaptation.
Conclusions
Abomasal infusions of both starch and oligofructose resulted in similar changes in fecal characteristics, suggesting that either can be an effective model of simulating changes in hindgut fermentation that accompany SARA. Splitting a single pulse dose into 4 smaller doses was likely more representative of SARA conditions because it should have resulted in more consistent delivery of fermentable carbohydrates to the intestines. Compared with the single dose, the 4 smaller doses dampened changes in fecal score, pH, and SCFA and likely reduced the osmotic challenge expected from a single pulse dose.
Abomasal infusion of SB increased NDF digestion before challenge and modestly improved fecal changes in response to abomasal oligofructose, suggesting that direct fed microbials may modify intestinal fermentation in dairy cows.
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